Microvention Costa Rica Plant Opening

TUSTIN, CA. – March 6, 2013 MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced that its new manufacturing facility in San José, Costa Rica is now open. The Company also held a Grand Opening Ceremony today to commemorate this exciting new venture for MicroVention. The new plant represents MicroVention’s first manufacturing facility outside the United States and the first Neurovascular manufacturing facility in Costa Rica, which is located at the Coyol Free Zone in the Alajuela region of Costa Rica.

The Plant Opening Ceremony was attended by numerous dignitaries and executives from the business district including the Vice President of Costa Rica, Luis Lieberman Ginsburg. Other executives who attended from MicroVention’s parent company included Mr. Yutaro Shintaku, President and Representative Director; Mr. Shinjiro Sato, Senior Executive Officer, Group President, Cardiac and Vascular Business Group, both of Terumo Corporation located in Tokyo, Japan and Mr. Hideo Arase, President and CEO of Terumo Americas Holding. Also in attendance was the Costa Rican Investment Promotion Agency (CINDE) which has supported MicroVention in establishing its plant in Costa Rica. “MicroVention will be the first company specializing in the neurovascular segment, and we are excited to welcome MicroVention to the Alajuela region,” commented Gabriela Llobet, CINDE´s Director General.

This new facility will support the growth and expansion of products offered under the MicroVention and Terumo brand and the Company has hired approximately 150 Associates with plans to expand in the coming months/years. The new plant is located just outside of San José, the nation’s capital (the size of the new facility is 7,500 M2 /80,000 sq. ft. and will encompass a 2,300 M2 clean room/25,000 sq. ft.). “We are very excited about the initiation of our first manufacturing facility in Costa Rica and commemorating the opening with many of our new partners celebrating with us. Our intent was to create a world-class facility extension of our corporate manufacturing plant in Tustin, CA, USA, and we have achieved that goal today,” said Richard Cappetta, President and Chief Executive Officer of MicroVention, Inc. In attendance besides the Company’s President and CEO were several other members of the MicroVention Executive Staff including William R. Hughes, Chief Operating Officer and Treasurer; Cherie Henket, Vice President, Human Resources; Matt Fitz, Sr. Vice President, Research and Development and Operations; Mr. Uichi Okina, Vice President, Strategic Planning, Business Development; and Charlie Noel, Vice President, Operations.

Approximately 12,000 people currently work in the Life Sciences Sector in Costa Rica with 41 medical device companies producing orthopedic, cardiovascular, women´s health devices, and medical supplies. Microvention will be the first company specializing in the neurovascular segment in Costa Rica. Microvention has been recruiting its first employees, specifically in the areas of Engineering, Quality, Production and Administration. Persons interested in applying can visit the “Careers – Costa Rica” page of the Terumo Neuro website at www.Microvention.com.

About Terumo Corporation

Tokyo‐based Terumo Corporation is one of the world’s leading medical device manufacturers with $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation’s shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol , or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan’s leading stock index.

About Terumo Neuro

Microvention is a U.S. subsidiary of Terumo Corporation with its corporate headquarters in Tustin, California, and manufacturing and administrative facilities in Santa Ana and Aliso Viejo, California, and San José, Costa Rica. Microvention is a developer, manufacturer and marketer of innovative neuroendovascular technologies for the treatment of vascular diseases in small vessels. Microvention products are sold throughout the world in more than 60 countries. For more information, visit www.Microvention.com.

Media Contact:

Cathy Demyanovich

Sr. Director, Corporate Communications

Terumo Neuro

800-990-8361

714-247-8000

MM284 2/2013